Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(6):375; doi:10.1093/jnci/djn067
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Adjuvant Chemotherapy After Gastric Cancer Surgery

The value of adjuvant chemotherapy in patients who have undergone complete surgical resection for gastric cancer is not clear. Di Costanzo et al. (p. 388) randomly assigned 258 patients who had been surgically treated for gastric cancer to intravenous treatment with four cycles of chemotherapy that consisted of cisplatin, epirubicin, leucovorin, and flurouracil (PELF) or to follow-up alone. Chemotherapy did not increase disease-free or overall survival. The authors stress the need for additional trials to test newer drug combinations and to analyze the association of clinical variables and molecular factors with survival.

In an editorial, Wu and . . . [Full Text of this Article]

Specialized Care and Survival of Dutch Ovarian Cancer Patients

Risk Factor Profiles for HPV-16–Positive and –Negative HNSCCs

COX-2 in Atypical Hyperplasia and Breast Cancer Risk

Cancer in Atomic Bomb Survivors Exposed In Utero or in Childhood

Genetic Variations in AKAP9 and Breast Cancer Risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers
Maura L. Gillison, Gypsyamber D'Souza, William Westra, Elizabeth Sugar, Weihong Xiao, Shahnaz Begum, and Raphael Viscidi
J Natl Cancer Inst 2008 100: 407-420. [Abstract] [Full Text] [PDF]

Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study
Flora Vernooij, A. Peter M. Heintz, Petronella O. Witteveen, Margriet van der Heiden-van der Loo, Jan-Willem Coebergh, and Yolanda van der Graaf
J Natl Cancer Inst 2008 100: 399-406. [Abstract] [Full Text] [PDF]

Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer
Daniel W. Visscher, V. Shane Pankratz, Marta Santisteban, Carol Reynolds, Ari Ristimäki, Robert A. Vierkant, Wilma L. Lingle, Marlene H. Frost, and Lynn C. Hartmann
J Natl Cancer Inst 2008 100: 421-427. [Abstract] [Full Text] [PDF]

Association of a Common AKAP9 Variant With Breast Cancer Risk: A Collaborative Analysis
Bernd Frank, Miriam Wiestler, Silke Kropp, Kari Hemminki, Amanda B. Spurdle, Christian Sutter, Barbara Wappenschmidt, Xiaoqing Chen, Jonathan Beesley, John L. Hopper, Australian Breast Cancer Family Study Investigators,, Alfons Meindl, Marion Kiechle, Tracy Slanger, Peter Bugert, Rita K. Schmutzler, Claus R. Bartram, Dieter Flesch-Janys, Elke Mutschelknauss, Katie Ashton, Ramona Salazar, Emily Webb, Ute Hamann, Hiltrud Brauch, Christina Justenhoven, Yon-Dschun Ko, Thomas Brüning, Isabel dos Santos Silva, Nichola Johnson, Paul P. D. Pharoah, Alison M. Dunning, Karen A. Pooley, Jenny Chang-Claude, Douglas F. Easton, Julian Peto, Richard Houlston, Gene Environment Interaction and Breast Cancer in Germany Group, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer Investigators, Australian Ovarian Cancer Study Management Group, Georgia Chenevix-Trench, Olivia Fletcher, and Barbara Burwinkel
J Natl Cancer Inst 2008 100: 437-442. [Abstract] [Full Text] [PDF]

Solid Cancer Incidence in Atomic Bomb Survivors Exposed In Utero or as Young Children
Dale L. Preston, Harry Cullings, Akihiko Suyama, Sachiyo Funamoto, Nobuo Nishi, Midori Soda, Kiyohiko Mabuchi, Kazunori Kodama, Fumiyoshi Kasagi, and Roy E. Shore
J Natl Cancer Inst 2008 100: 428-436. [Abstract] [Full Text] [PDF]

Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC
Francesco Di Costanzo, Silvia Gasperoni, Luigi Manzione, Giancarlo Bisagni, Roberto Labianca, Stefano Bravi, Enrico Cortesi, Paolo Carlini, Raffaella Bracci, Silverio Tomao, Luca Messerini, Annarosa Arcangeli, Valter Torri, Domenico Bilancia, Irene Floriani, and Maurizio Tonato On behalf of Italian Oncology Group for Cancer Research
J Natl Cancer Inst 2008 100: 388-398. [Abstract] [Full Text] [PDF]

Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?
Aiwen Wu and Jiafu Ji
J Natl Cancer Inst 2008 100: 376-377. [Extract] [Full Text] [PDF]

Enhancing Cancer Registry Data to Promote Rational Health System Design
Deborah Schrag
J Natl Cancer Inst 2008 100: 378-379. [Extract] [Full Text] [PDF]